Shared on19 May 25Fair value Decreased 1.86%
Zwfis made no meaningful changes to valuation assumptions.
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
Zwfis's Fair Value
US$4.23
60.8% undervalued intrinsic discount19 May
US$1.66
1Y
71.5%7D
12.2%